NeuroMetrix Gets Sleep-Monitoring Patent

NeuroMetrix said early Tuesday it has received a patent for a technology whereby the company’s Quell device automatically modulates therapeutic neurostimulation based on the user’s sleep characteristics.In addition, the patent from the U.S. Patent and Trademark Office includes claims related to providing users with feedback about their sleep, the company said in a statement.

The company said Quell is the only transcutaneous electrical nerve stimulator cleared by the Food and Drug Administration for use during sleep that is available over the counter. It also measures and tracks sleep data to help users understand the amount and quality of their sleep. “This patent further expands our wearable pain relief intellectual property assets and enhances our long-term competitive position,” the company said.

Leave a Comment